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Abstract
Background: The commercial Kalon HSV-2 IgG ELISA is currently recommended for research use in sub-Saharan
Africa because of its superior accuracy compared to other serologic assays. However, there are no data on key
precision parameters of Kalon such as inter-operator variation, repeatability, and reproducibility, thus contributing to
a barrier for its acceptance and use in clinical trials in sub-Saharan Africa. We evaluated the analytical and field
precision of the Kalon HSV-2 IgG ELISA.
Methods: A total of 600 HIV-infected and uninfected serum samples from South Africa and Zambia, previously
tested by the gold standard University of Washington HSV western blot (UW-WB), were tested using Kalon by two
technologists in an United States reference laboratory. Aliquots of 183 samples were retested using Kalon by an
on-site technologist in a South African laboratory and a Zambian laboratory.
Results: Intra-assay variation was below 10 %. Intra-assay, intra-laboratory, and inter-laboratory correlation and
agreement were significantly high (p < 0.01). In comparison to the UW-WB, accurate performance of Kalon was
reproducible by each operator and laboratory. Receiver operating characteristic curve analysis indicated high
selectivity of Kalon in the overall study population (area under the curve = 0.95, 95%CI = 0.92–0.97).
Discussion: Kalon is a robust assay with high precision and reproducibility. Accordingly, operator errorlikely does
not contribute to the variability observed in Kalon’s specificity throughout sera from sub-Saharan Africa.
Conclusions: In populations with optimal diagnostic accuracy, Kalon is a reliable stand-alone method for on-site
HSV-2 IgG antibody detection.
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Background
Herpes simplex virus type 2 (HSV-2) infection is difficult
to diagnose during subclinical periods. If a patient does
present with symptoms, the infection is initially diag-
nosed by PCR or viral culture, and is confirmed by de-
tection of IgG antibody for glycoprotein G-2 (gG2) [1].
Serological screening is also recommended in several
high-risk populations [1, 2]. Additionally, HSV-2 serosta-
tus is a common biomarker in epidemiological research
and clinical trials [3–6]. Thus, serologic tests for gG2 are
important for the treatment, prevention and study of
HSV-2 infection [1, 7].
A gold standard test is the University of Washington
HSV Western blot (UW-WB). However, the UW-WB is
expensive and technically difficult for screening and clin-
ical trials [1, 8]. Alternatively, there are commercial
enzyme-linked immunosorbent assays (ELISAs). The
FDA-cleared Focus HerpeSelect-2 IgG ELISA (“Focus”)
has been the popular assay in both clinical and research
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settings, while the Kalon HSV-2 IgG ELISA (“Kalon”) is
not FDA-approved and is only recommended for use in
secondary research. Both assays have optimal accuracy
in industrialized countries, but their performance on
sera from developing countries has varied [9–12].
A recent meta-analysis described better overall accuracy
of Kalon than Focus in the same study population in sub-
Saharan Africa [9]. For Focus, sensitivity and specificity
were 99 and 69 %, respectively, at the manufacturers’ index
cut-off (>1.1), and were 91 and 85 %, respectively, at an
increased cut-off (>3.5). Kalon’s sensitivity and specificity at
the manufacturer’s index cut-off (>1.1) were 95 and 91 %,
respectively. For both assays, there is heterogeneity in their
specificity between study populations within sub-Saharan
Africa, however this heterogeneity is more pronounced for
Focus [9, 11–18]. Kalon has also been shown to be more
specific than Focus in developing countries beyond sub-
Saharan Africa such as Papau New Guinea [19]. Even
though Kalon often has higher specificity than Focus, there
are situations where the higher sensitivity of Focus is more
desirable. For example, Legoff et al. (2008) found that Kalon
misses primary infections more frequently than Focus when
screening populations presenting with genital ulcerations
[1, 20]. Thus, it is recommended to evaluate the accuracy
of both assays prior to use in intended populations to select
the most appropriate assay and cut-off [9].
Although the accuracy of Kalon has been extensively
studied, its precision parameters have not been previously
described by the manufacturer or in the literature. This
knowledge is essential for any use of Kalon. This is particu-
larly important for its expected expansion from epidemio-
logic research to clinical trials in sub-Saharan Africa, and in
populations where its diagnostic accuracy is superior to that
of Focus. Therefore, the primary aim of this study was to
evaluate the precision of the Kalon HSV-2 IgG ELISA. We
also examine its accuracy compared to UW-WB among
Zambian and South African sera.
Methods
Ethics statement
The present investigation was conducted according to
the principles expressed in the Declaration of Helsinki.
The Partners in Prevention HSV/HIV Transmission Study
protocol and the procedure for written informed consent
was approved by the University of Washington Human
Subjects Review Committee and the ethics review commit-
tees at other organizations involved in the collaboration
(Additional file 1) [21]. All participants provided written
informed consent and consented serum samples for long-
term storage [21].
Sample population
Samples came from the Partners in Prevention HSV/HIV
Transmission Study. The protocol for the Partners Study
has been previously described [6, 21]. In brief, the study
enrolled 3408 HSV-2/HIV-1 co-infected individuals and
their HIV-uninfected heterosexual partners from seven
African countries (Botswana, Kenya, Rwanda, South Africa,
Tanzania, Uganda and Zambia) between November 2004
and April 2007. Participants were ≥18 years of age and pro-
vided written informed consent. Serum samples were con-
sented for long-term storage in the U.S.A. and were stored
at −80 °C.
For the present analysis, samples (N = 600) were ran-
domly selected without replacement within the following
criteria: (1) de-identified serum from study enrollment in
the Partners Study, (2) had UW-WB HSV-2 results readily
available, and (3) 300 samples each from South Africa and
Zambia. We selected sera from South Africa and Zambia
due to availability of sample volume and because the per-
formance of Kalon compared to the UW-WB is unknown
in Zambian sera.
Laboratory testing
All HSV-2 testing by the Kalon HSV-2 IgG ELISA (Kalon
Biological Ltd., U.K.) was manually conducted between
September and November 2013 using the same kit lot
number. Kalon testing was performed per manufacturer
protocol unless otherwise stated. All samples (N = 600)
were first tested at the HIV Prevention Trials Network
(HPTN) Laboratory Center at the Johns Hopkins Univer-
sity in Baltimore, MD, U.S.A. The HPTN Laboratory Cen-
ter conducts retrospective QA/QC testing for HPTN
trials, and samples were tested in duplicate (within-run)
by an operator with >9 years of laboratory experience
(“Technologist-Sr.”). Testing was repeated in duplicate
(within-run) by an operator with <1 year of laboratory ex-
perience and no previous experience running serological
assays (“Technologist-Jr.”). A subset of samples (n = 183)
were selected based on available volumes, and separate ali-
quots of the same sample were shipped on dry ice to a
field HPTN laboratory site in South Africa (SA) and
Zambia (ZM). Samples were re-tested in singlet by a lead
on-site operator (“Technologist-SA” and “Technologist-
ZM”), and again by Technologist-Sr. at the South African
laboratory site.
The manufacturer’s calibrator was run in duplicate
on all plate runs in the study. The absorbance of the
plate was read by a spectrophotometer. Plate readers
at the South African and Zambian laboratory sites had
an upper limit of detection of 3.0 optical density (OD)
units, while the plate reader at the HPTN Laboratory
Center did not have this upper limit. The OD units
were used to calculate the manufacturer’s index value
cut-offs (<0.9, negative; 0.9–1.1, indeterminate; >1.1
positive) as per the manufacturer’s protocol. The pre-
viously known UW-WB HSV-2 result was considered
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the ‘gold-standard’, and operators were blinded to these
data.
Statistical analyses
Analytical precision was defined as intra-assay (within-
run) and inter-assay (between-run) repeatability of re-
sults produced by Kalon, as performed by Technologist-Jr.
and Technologist-Sr. at the HPTN Laboratory Center.
Intermediate precision was determined by evaluating
intra-laboratory repeatability of Kalon at the HPTN La-
boratory Center and the South African laboratory. Field
precision of Kalon was assessed as inter-operator repeat-
ability between all laboratory sites.
Continuous and categorical statistical parameters were
used to assess repeatability for each type of precision.
Continuous variables, such as the OD units of manu-
facturer’s calibrator and Kalon index values for serum
samples, were analyzed using the coefficient of vari-
ation (CV) and Pearson’s correlation coefficient (r).
Differences in mean and median Kalon index values be-
tween operators were determined by the two-sample
Wilcoxon rank-sum (Mann–Whitney) test. Since Kalon
is intended to be a qualitative assay, the categorical
agreement of results (negative, indeterminate, positive)
was determined within and between operators and la-
boratory sites using the Cohen’s Kappa coefficient (κ).
A κ-value between 0.80–0.90 and 0.90–1.0 denotes
strong and almost perfect agreement, respectively [22].
Field precision of Kalon was further characterized by
comparing the inter-operator and inter-laboratory reprodu-
cibility of accurate results compared to UW-WB as the
‘gold-standard’. This reproducibility analysis excluded inde-
terminate samples by the UW-WB (n = 3), and was re-
peated using three scenarios: 1) considered indeterminate
samples by Kalon as positive; 2) considered indeterminate
samples by Kalon as negative; and 3) removed indetermin-
ate samples by Kalon. Accuracy was characterized by
sensitivity and specificity (calculated using standard for-
mulas), and by receiver operator characteristics curve
(ROC) analysis. ROC curves illustrate the sensitivity
versus 1-specificity (false-positive rate) of an assay, and
the area under the curve (AUC) is indicative of diag-
nostic selectivity. An AUC of 1.0 represents a ‘perfect
test’ [23].
To assess the optimal index cutoff (1.1 vs 1.5) of Kalon
and allow stratification by characteristics of the study
population, accuracy of Kalon compared to the UW-WB
was determined for the entire study population using
Technologist-Sr.’s results from the HPTN Laboratory
Center. This analysis excluded 16 indeterminate samples
by the UW-WB and considered 10 indeterminate samples
by Kalon as negative. Differences in study population
characteristics were determined by Pearson’s χ2 test and
two-sample Wilcoxon rank-sum (Mann–Whitney) test for
categorical and continuous variables, respectively. Statis-
tical significance was considered as P < 0.05, and 95 %
confidence intervals (CI) were calculated from a binomial
distribution. Statistical analyses were performed in
STATA version 14 (StataCorp, College Station, TX)




Of the total 600 samples, 305 were from males, 300 were
HIV positive, and the median age was 32 (IQR = 27–39).
Two samples had missing gender and age data. The
sample population included sera collected from 14 indi-
viduals with a medical history of GUD within the past
3 months and 13 individuals with clinical presentation of
GUD by physical examination at the time of sample
collection (4 samples were positive by both approaches);
one sample was missing for GUD status by physical
examination and medical history. By UW-WB, 106 sam-
ples were seronegative, 478 samples were seropositive,
and 16 samples had indeterminate results. Of the 300
HIV positive samples, 99.3 % were HSV-2 seropositive
by UW-WB.
Analytical precision
Intra-assay variation of the manufacturer kit calibrator’s
OD units, as performed at the HPTN Laboratory Center,
was CV = 5.4 % (CV = 4.2 % for Technologist-Jr. and
6.5 % for Technologist-Sr.; n = 13 plate runs per oper-
ator). Consistent with these results, the average intra-
assay variation in sample index values for both operators
was also low (CV = 6.3 %; n = 1196). Categorical intra-
assay agreement was ‘almost perfect’ for both operators,
but was higher for Technologist-Sr. (κ = 0.96) compared
to Technologist-Jr. (κ = 0.91; Table 1). Inter-assay
variation of the manufacturer kit calibrator’s OD units
was CV = 10.2 % (CV = 8.7 % for Technologist-Jr. and
CV = 11.8 % for Technologist-Sr. for plate runs per-
formed at the HPTN Laboratory Center (n = 13 plate
runs per operator). The same operator did not retest
serum samples on different plate runs so inter-assay re-
peatability of Kalon index values could not be assessed.
Table 1 Intra-assay (within-run) repeatability of the Kalon HSV-2
IgG ELISAa
Operator N CV r Agreement b κ b
Technologist-Jr. 598 6.7 % 0.99* 96.8 % 0.91*
Technologist-Sr. 598 5.9 % 0.98* 98.7 % 0.96*
Abbreviations: CV coefficient of variation, r Pearson’s correlation coefficient, and
κCohen’s kappa coefficient
*P < 0.01
aData based Kalon as performed at the USA site (HPTN Laboratory Center)
bAgreement was based on categorical results interpreted by the manufacturer’s
index cut-offs (<0.9, negative; 0.9–1.1, indeterminate; >1.1 positive)
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Intermediate precision
Figure 1 depicts the intra-laboratory repeatability of Kalon
for all samples tested at the HPTN Laboratory Center.
Kalon index values for samples run by Technologist-Jr.
(median = 2.48; IQR = 0.42–5.34) and Technologist-Sr.
(median = 2.42; IQR = 0.49–5.48) at the HPTN Laboratory
Center were not significantly different (P = 0.567; Fig. 1a).
The sample Kalon index values between both operators
had an average CV of 12.8 % and were significantly corre-
lated (P < 0.01; Fig. 1b). There was ‘almost perfect’ inter-
operator agreement between operators within the HPTN
Laboratory Center (κ = 0.90; n = 596; Fig. 1c).
In the subset of 183 samples, variation in Kalon index
values between operators was twice as high at the South
African site (CV = 18.8 %) compared to variation between
operators at the HPTN Laboratory Center (CV = 9.6 %).
Both correlation (r = 0.89) and agreement (κ = 0.89) be-
tween operators in the South African laboratory were
significantly high, but were lower in comparison to intra-
laboratory performance at the HPTN Laboratory Center.
Field precision
The mean calibrator OD units were significantly higher
in the Zambian and South African laboratory sites com-
pared to performance at the HPTN Laboratory Center
(Fig. 2). Of the 183 samples tested by all operators, 13
samples had an OD > 3.0 in the HPTN Laboratory Cen-
ter and were excluded from continuous comparisons.
The mean Kalon index value was significantly higher at the
HPTN Laboratory Center (mean index: 2.87) compared to
the South African laboratory site (mean index = 1.68) and
Zambian laboratory site (mean index = 1.72; P < 0.01). The
differences in the mean index value between the
South African and Zambian laboratories were not sig-
nificant (P = 0.921). Fig. 3a depicts the range of Kalon
index values for all operators (n = 170). Inter-laboratory
variation was higher than intra-laboratory variation, with
the CV ranging from 30.5 to 46.1 % (n = 170; Fig. 3b).
There was, however, ‘strong’ or ‘almost perfect’ agree-
ment between all operators (P < 0.01; n = 183; Fig. 3c).
Fig. 3c presents the Kalon index values for all samples
that were categorically discordant by Kalon between op-
erators. Of the 13/183 samples, 8 samples were consid-
ered discordant solely because of indeterminate result(s),
as in these samples did not have conflicting results of
positive vs. negative between operators. Excluding the 8
indeterminate samples resulted in an overall discordance
rate of 2.9 % (5/175) between operators. The majority of
samples (10/13) that were discordant between operators
were HSV-2 seropositive by UW-WB (Fig. 3c) and none
presented with GUD by physical examination or their
past medical history (3 months).
In addition to consistency of Kalon results between
operators and field sites, the categorical results produced
by Kalon and each operator were accurate compared to
UW-WB. Performance of Kalon in terms of sensitivity,
specificity, and diagnostic selectivity were similar by all
operators and field sites (cut-off = 1.1; Table 2). Consider-
ing indeterminate samples by Kalon as negative, positive, or
excluding them from this analysis had no significant effect
on the statistical parameters (Table 2).
Diagnostic accuracy
In the overall study population, the optimal cut-off was
1.1 (AUC = 0.95, 95 % CI = 0.92, 0.97) when excluding
16 indeterminate UW-WB samples and considering 10
indeterminate Kalon results as negative (Table 3). Coun-
try of origin did not significantly affect the diagnostic
accuracy as defined by the AUC, however, specificity was
lower in Zambian sera (88.7, 95 % CI = 77.0, 95.7) than
Fig. 1 The intermediate precision of the Kalon HSV-2 IgG ELISA (N = 596). These data are based on the performance of Kalon by Technologist-Jr.
and Technologist-Sr. at the HPTN Laboratory Center in the USA. a Shows box plots that represent the range, interquartile range, and median
Kalon index values for all samples tested by both operators. b Shows the correlation and variability in Kalon index values between operators.
c Presents the agreement of categorical results between operators as determined by the manufacturer’s index cut-offs (<0.9, negative; 0.9–1.1,
indeterminate; >1.1 positive)
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in South African sera (98.1, 95 % CI = 89.9, 100.0; Table 3).
Of note, sera from Zambia were more likely to be from
older (P = 0.021) and HIV positive (P = 0.012) individuals
compared to sera from South Africa. Although there was a
slightly higher prevalence of GUD in sera from Zambia
compared to South Africa, the difference was not signifi-
cant (Table 3). Additionally, all GUD positive samples by
physical examination and medical history were concor-
dantly seropositive by UW-WB and Kalon. Raising the cut-
off to 1.5 improved specificity in Zambian sera, but had no
significant effect on diagnostic selectivity since it also de-
creased the assay’s sensitivity from 97.0 % (cut-off = 1.1) to
92.3 % (cut-off = 1.5) (Table 3).
Due to the high seroprevalence of HSV-2 (99.3 %)
among the HIV positive samples, specificity and the AUC
for this population could not be assessed. Characteristics
of the indeterminate samples by UW-WB and Kalon are
presented in Table 4. Of the 16 indeterminate samples by
UW-WB, 10 (62.5 %) were positive by Kalon. No indeter-
minate samples by UW-WB or Kalon had symptoms of
GUD in their medical history (past 3 months) or had
physical presentation of GUD (Table 4).
Discussion
It is estimated that 19.2 million individuals were newly
infected with HSV-2 infection in 2012. Given the
global estimate of HSV-2 prevalence of 11.3 %, with
significant burden in sub-Saharan Africa (32 %) [24], it
is essential to keep clinicians and researchers informed
of all characteristics of HSV diagnostics. Unlike FDA-
approved, commercially available, serologic HSV-2 as-
says, the Kalon HSV-2 IgG ELISA has not been rigor-
ously assessed beyond diagnostic accuracy. This study
demonstrates that Kalon has a high level of analytical
precision. Despite inter-laboratory variation in its op-
tical density and index values, this qualitative ELISA
was able to consistently categorize HSV-2 serostatus
within and between a quality assurance site and field
Fig. 2 The mean optical density of the Kalon HSV-2 IgG ELISA calibrator
for all plate runs in the study
Fig. 3 The field precision of the Kalon HSV-2 IgG ELISA. a Shows box plots that represent the range, interquartile range, and median Kalon index
values for samples tested by all operators (n = 170). The star and pound signs represent inter-operator comparisons by the Wilcoxon rank-sum test.
b Shows the correlation and variability in Kalon index values between operators and also presents the agreement of categorical results between
operators as determined by the manufacturer’s index cut-offs (<0.9, negative; 0.9–1.1, indeterminate; >1.1 positive); (n = 170). c Depicts any sample
that had a Kalon result that was discordant from other Kalon results by all operators (n = 183). The a indicates that these results were generated
by Technologist-Sr. in South Africa
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Table 3 Diagnostic accuracy of the Kalon HSV-2 IgG ELISA compared to UW-WB in South African and Zambian sera (N = 600) a
Characteristic Country of origin HIV status Total (n/N)
South Africa Zambia HIV negative HIV positive
HSV-2 Prevalence by UW-WB, % (95 % CI) 82.1 (77.2, 86.3) 81.6 (76.6, 85.9) 63.9 (58.0, 69.4) 99.3 (97.6, 99.9) 81.9 (478/584)
GUD Presentation by Physical Exam, % (95 % CI) 1.4 (0.4, 3.4) 3.5 (1.7, 6.3) 0.7 (0.1, 0.2) 4.1 (2.1, 7.0) 2.4 (14/583)
Medical History of GUD in past 3 months, % (95 % CI) 1.7 (0.6, 3.9) 3.1 (1.4, 5.8) 0.7 (0.1, 0.2) 4.1 (2.1, 7.0) 2.4 (14/583)
HIV Prevalence, % (95 % CI) 49.7 (43.8, 55.5) 51.7 (45.8, 57.6) – – 50.7 (296/584)
Median Age (IQR) 31.6 (27.1, 37.4) 32.2 (27.2, 41.7) 33.4 (28.0, 39.6) 31.1 (26.3, 37.6) 32.0 (27.1, 38.7)
Kalon Performance (cut-off = 1.1)
Sensitivity, % (95 % CI) 94.2 (90.5, 96.8) 97.0 (94.0, 98.8) 94.0 (89.6, 97.0) 96.6 (93.8, 98.4) 95.6 (93.4, 97.3)
Specificity, % (95 % CI) 98.1 (89.9, 100.0) 88.7 (77.0, 95.7) 94.2 (87.9, 97.9) – 93.4 (86.9, 97.3)
AUC (95 % CI) 0.96 (0.94, 0.99) 0.93 (0.88, 0.97) 0.94 (0.91, 0.97) – 0.95 (0.92, 0.97)
Kalon Performance (cut-off = 1.5)
Sensitivity, % (95 % CI) 92.2 (88.1, 95.2) 92.3 (88.2, 95.4) 88.6 (83.1, 92.8) 94.6 (91.3, 96.9) 92.3 (89.5, 94.5)
Specificity, % (95 % CI) 98.1 (89.9, 100.0) 92.5 (81.8, 97.9) 96.2 (90.4, 98.9) – 95.3 (89.3, 98.5)
AUC (95 % CI) 0.95 (0.93, 0.98) 0.92 (0.88, 0.96) 0.92 (0.89, 0.95) – 0.94 (0.91, 0.96)
Abbreviations: UW-WB, University of Washington HSV Western Blot; CI, confidence interval; GUD, Genital Ulcer Disease, AUC, area under the curve
aIndeterminate results by UW-WB were excluded in the analysis (n = 16). Kalon data are based on its performance by Technologist-Sr. at the HPTN Laboratory
Center, and indeterminate results by Kalon (n = 10) were considered seronegative
Table 2 Accurate reproducibility of the Kalon HSV-2 IgG ELISA (N = 183; HSV-2 prevalence = 72 %) a
Kalon conditions Sensitivity, % (95 % CI) Specificity, % (95 % CI) AUC (95 % CI)
IND as NEG b
Technologist-Jr. 90.1 (83.6–94.6) 100.0 (92.7–100.0) 0.95 (0.93–0.98)
Technologist-Sr. e 92.4 (86.4–96.3) 95.9 (86.0–99.5) 0.94 (0.91–0.98)
Technologist-Sr. f 94.7 (89.3–97.8) 98.0 (89.1–99.9) 0.96 (0.94–0.99)
Technologist-SA 88.5 (81.8–93.4) 100.0 (92.7–100.0) 0.94 (0.92–0.97)
Technologist-ZM 93.1 (87.4–96.8) 98.0 (89.1–99.9) 0.96 (0.93–0.98)
IND as POS c
Technologist-Jr. 93.1 (87.4–96.8) 98.0 (89.1–99.9) 0.96 (0.93–0.99)
Technologist-Sr. e 94.7 (89.3–97.8) 95.9 (86.0–99.5) 0.95 (0.91–0.99)
Technologist-Sr. f 96.2 (91.3–98.7) 98.0 (89.1–99.9) 0.97 (0.95–1.00)
Technologist-SA 91.6 (85.5–95.7) 95.9 (86.0–99.5) 0.94 (0.90–0.97)
Technologist-ZM 94.7 (89.3–97.8) 98.0 (89.1–99.9) 0.96 (0.94–0.99)
IND excluded d
Technologist-Jr. 92.9 (87.0–96.7) 100.0 (92.6–100.0) 0.97 (0.94–0.99)
Technologist-Sr. e 94.5 (89.1–97.8) 95.9 (86.0–99.5) 0.95 (0.92–0.99)
Technologist-Sr. f 96.1 (91.2–98.7) 98.0 (89.1–99.1) 0.97 (0.94–1.00)
Technologist-SA 91.3 (85.0–95.6) 100.0 (92.5–100.0) 0.96 (0.93–0.98)
Technologist-ZM 94.6 (89.1–97.8) 98.0 (89.1–99.9) 0.96 (0.94–0.99)
Abbreviations: POS positive, NEG negative, IND indeterminate, CI confidence interval, AUC area under the receiver operating characteristic curve
aGold standard: UW-WB; indeterminate results by UW-WB were excluded in the analysis (n = 3)
bIndeterminate results by Kalon were considered as negative in the analysis
cIndeterminate results by Kalon were considered as positive in the analysis
dIndeterminate results by Kalon were excluded in the analysis
eKalon was performed at the HPTN Laboratory Center (USA site)
fKalon was performed in the South African laboratory
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laboratories. Optimal reproducibility of Kalon was main-
tained across operators with varying levels of experience
running serological assays. Taken together, in study popu-
lations where its accuracy compared to UW-WB is opti-
mal, Kalon should be considered a reliable test for HSV-2
serodiagnostics.
Resource-limited settings are heavily burdened by HSV-2
infection. Although Kalon has been shown to have optimal
accuracy in several populations, its utility in field research
laboratories has not been widely accepted. The optimal re-
peatability of Kalon observed in this analysis suggests that
Kalon can be performed in resource-poor regions as a
stand-alone method for HSV-2 serology. This is especially
important for large-scale HIV/HSV-2 epidemiological in-
vestigations such as the HPTN 071 PopART community
randomized trial in South Africa and Zambia [25, 26].
Rather than shipping all samples to laboratories in devel-
oped countries solely for HSV-2 screening, use of Kalon by
on-site operators in field laboratories is a more feasible and
cost-effective alternative.
This study confirms that Kalon can perform accurately
compared to UW-WB. Specificity of Kalon, compared to
the UW-WB, was previously unknown in Zambia, how-
ever, our finding of 98.1 % specificity in South Africa is
higher but comparable to a study that found 85 % (95 %
CI, 61–100 %) specificity (index cut-off = 1.1) [18]. Speci-
ficity was slightly lower in Zambian sera (88.7 %; index
cut-off = 1.1) compared to in South African sera in this
study population, and it was previously noted that
operator error might explain the variability of Kalon’s
specificity throughout sub-Saharan Africa [8, 9]. How-
ever, our study reveals that differential laboratory perform-
ance of Kalon is likely not a major contributor to regional
differences in its accuracy compared to UW-WB.
The regional variability in Kalon’s specificity observed
in this study may be in part due to differences in study
population characteristics. Although this study was not
powered to assess the effect of HIV on Kalon’s specifi-
city, previous studies have reported reduced specificity
among HIV-infected individuals and our study had a
slightly higher HIV prevalence in the Zambian vs. South
African study population [9, 18]. As hypothesized by previ-
ous serodiagnostic validation studies, lower specificity of
Kalon compared to UW-WB may also be due to cross-
reactivity with unidentified antibodies or a nucleotide poly-
morphism in the gG2 sequence among African populations
[8, 9, 12, 14]. Recent studies support the latter hypothesis
as we now know there is regional nucleotide and antigenic
variation in the HSV glycoprotein—the diagnostic target of
HSV serologic assays [27, 28]. Until improved serologic
assays are available, it remains necessary to evaluate Kalon’s
accuracy in proposed populations prior to their utility [9].
This study had several limitations. In terms of the ana-
lytic precision analysis, we did not evaluate differential
lot performance. Although we report inter-laboratory vari-
ability in the OD and Kalon index values, we did not iden-
tify operational (equipment) and environmental factors (e.g.
temperature, pH of water, and humidity) that may have
contributed to inter-laboratory variability. Further work is
needed to pinpoint why the OD values were higher at the
Table 4 Characteristics of the indeterminate samples by UW-WB and Kalon (index cut-off = 1.1)
Indeterminate by UW-WB Indeterminate by Kalon (index: 0.9–1.1) a
Total (No.) 16 10
GUD Presentation by Physical Exam (No.) 0 0
Medical History of GUD in past 3 months (No.) 0 0
HIV Prevalence, % (n/N) 25.0 (4/16) 30.0 (3/10)
Median Age, years (IQR) 33.0 (25.9, 39.2) 31.4 (26.4, 35.8)
Country of Origin (No.)
South Africa 4 5
Zambia 12 5








Abbreviations: UW-WB University of Washington HSV Western Blot, GUD genital ulcer disease, and IQR interquartile range
aKalon results were produced in the HPTN Laboratory Center (USA site) by Technologist-Sr. and were interpreted by the manufacturer’s index cut-offs: (<0.9, negative;
0.9–1.1, indeterminate; >1.1, positive)
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sub-Saharan African sites compared to the United States.
In addition, due to the high HSV-2 seroprevalence in this
study population, the applicability of our accuracy analysis
may only apply to high prevalence settings where serocon-
version is a common event.
A limitation of serological assays in general is that they
may miss any persons undergoing seroconversion. One
study demonstrated that UW-WB and Kalon have a me-
dian time to seroconversion of 87 and 120 days, respect-
ively, thereby missing recently infected individuals [29].
We conservatively considered indeterminate results by
Kalon as negative in the accuracy analysis, but indeter-
minate results may be an indication of early seroconver-
sion [30]. Most indeterminate results by Kalon were
seropositive by UW-WB, and the majority of discordant
Kalon results between operators were also seropositive
by UW-WB. This suggests that Kalon may lack sensitiv-
ity compared to UW-WB. Interestingly, most indetermin-
ate samples by UW-WB were seropositive by Kalon.
Although indeterminate samples did not significantly affect
reproducibility, a higher prevalence of indeterminate sam-
ples in a study population may prove to be problematic for
other populations. The root cause for indeterminate sam-
ples, whether early seroconversion, genetic variation of the
infecting virus or cross-reactivity due to different infections,
warrants further investigation.
Meanwhile, indeterminate samples are challenging for
clinicians and researchers. In a clinical setting, indeter-
minate samples by Focus (currently used as a stand-
alone method) require follow-up testing at a later date
to demonstrate seroconversion. Alternatively, confirm-
ation testing by western blot is often conducted in clinical
trials where follow-up sera may not be available [21]. It
may be plausible to adapt the same testing algorithms for
Kalon. In secondary research studies, the protocol for
handling indeterminate samples will likely be dependent
on the study outcome. Further work is needed to develop
and optimize serologic HSV-2 assays, as serology remains
the test of choice for HSV-2 screening.
Conclusions
In summary, the Kalon HSV-2 IgG ELISA provides reli-
able results for determining HSV-2 serostatus. While it
is preferable to use FDA-cleared assays for diagnostics,
these data confirm that Kalon is a dependable replace-
ment for use in populations where its accuracy is super-
ior to current methods. These data also suggest that
Kalon can be utilized in field laboratories of resource-
limited settings, enhancing the feasibility to monitor the
epidemic and assess intervention efforts. Particularly in
sub-Saharan Africa where HSV-2 diagnostics are challen-
ging, it may be of benefit to extend Kalon’s utility beyond
epidemiological research.
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